This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Neurology  • Neuro-ophthalmology  • Drug Therapy  • Alert me on articles by topic

Fahhad I. Farukhi, MBA, MA; Kathryn Bollinger, MD; Paul Ruggieri, MD; Michael S. Lee, MD

Arch Ophthalmol. 2006;124:1055-1057.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A third nerve palsy (TNP) may show gadolinium enhancement of the cisternal segment of the oculomotor nerve on magnetic resonance imaging. Causes include inflammation, infection, neoplasm, ophthalmoplegic migraine, and demyelination. Infliximab, a tumor necrosis factor (TNF) inhibitor, may cause demyelination or increase relapses in patients with multiple sclerosis.¹ We report a patient who developed a TNP associated with infliximab use.

Report of a Case

A 47-year-old man with rheumatoid arthritis received monthly infusions of 300 mg of infliximab since December 2002. In February 2004, he was initially seen with painless ptosis of his right upper eyelid along with double vision in left and upgaze.

On examination, he had minimal ptosis and limitation of elevation and adduction of the right eye. Pupils were equal in size and reactivity. Visual acuity, dilated fundus examination, neurologic examination, and review of systems were . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION